Changes in Ocular Blood Flow after Ranibizumab Intravitreal Injection for Diabetic Macular Edema Measured Using Laser Speckle Flowgraphy

Table 4

Median (1st quartile–3rd quartile) computed for blowout score (BOS), blowout time (BOT), central macular thickness (CMT), and best-corrected visual acuity (BCVA) at baseline, time 1 (T1), and time 2 (T2).

Variables	Baseline	T1	T2	Friedman test
				value
BOS1	68.7 (60.2–71.4)	63.1 (58.4–70.6)	60.5 (44.9–70.5)	0.862
BOS2	53.6 (47.3–63.5)	56.7 (50.3–57.7)	51.4 (50.9–59.5)	0.292
BOS3	65.8 (60.5–79.3)	60.3 (50.9–74.8)	72.5 (35.4–75.8)	0.146
BOT1	47.6 (44.2–50.2)	42.6 (42.0–47.6)	54.4 (46.8–65.3)	0.001
BOT2	42.7 (34.3–58.1)	38.0 (28.0–39.4)	39.5 (33.5–51.4)	0.090
BOT3	48.3 (35.9–56.3)	39.9 (29.9–46.6)	50.3 (41.3–59.1)	0.583
CMT (μm)	452.0 (352.0–514.0)	400.0 (316.0–475.0)	313.0 (308.0–371.0)	0.005
BCVA (logMAR)	0.5 (0.50–0.60)	0.6 (0.50–0.70)	0.7 (0.70–0.80)	<0.001

multiple comparison test vs. previous time point.